[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shandong First Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":110},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,61,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100585257","phase-2-a-study-to-evaluate-cm336-in-adults-with-autoimmune-bullous-disease-100585257",false,"NCT06900010","A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease","An Open-label, PhaseⅡ Study to Evaluate the Efficacy and Safety of CM336 (BCMA\u002FCD3 Bispecific Antibody) in Adults With Moderate to Severe Autoimmune Bullous Disease","Inclusion Criteria:\n\n* 1\\. Confirmed diagnosis of autoimmune bullous disease；\n* 2\\. Age ≥18 years, regardless of gender；\n* 3\\. Voluntarily signed informed consent form, with understanding of the study's nature, purpose, procedures, and willingness to comply with trial requirements.\n\nExclusion Criteria:\n\n* 1\\. History of clinically significant diseases that, in the investigator's judgment, may pose safety risks to the subject during participation；\n* 2\\. Prior treatment with anti-B-cell maturation antigen (BCMA) therapy；\n* 3\\. History of allergic reactions to humanized monoclonal antibodies or known allergy to any component of CM336；\n* 4\\. Any other condition deemed by the investigator to render the subject unsuitable for study participation.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","to Evaluate the Efficacy and Safety of CM336 (BCMA\u002FCD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease",[26],"Autoimmune Bullous Disease","RECRUITING","2026-03-31",{"date":30,"type":31},"2026-04-06","ACTUAL",{"date":33,"type":31},"2025-04-22",{"date":35,"type":20},"2028-01-01",{"name":37,"class":38},"Shandong First Medical University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":39},"100618895","phase-2-a-clinical-study-evaluating-the-efficacy-and-safety-of-shr-1139-injection-in-adult-patients-with-ulcerative-pyoderma-gangrenosum-100618895","NCT07337564","A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum","Inclusion Criteria:\n\n* Male or female, age ≥ 18 years old at the time of signing the informed consent form (ICF).\n* Diagnosed with ulcerative PG during screening, and requiring systemic treatment as assessed by the investigator.\n* At screening and baseline, there is at least one measurable PG ulcer. If a subject has more than one PG ulcer, the investigator will select the target PG ulcer.\n* Subjects voluntarily sign informed consent form (ICF) prior to the commencement of any procedures related to the study, are able to communicate smoothly with the investigator, understand and are willing to complete the study in strict compliance with the requirements of this clinical study protocol.\n* Adequate organ and bone marrow function.\n* Female subjects of childbearing potential or male subjects whose partners are females of childbearing potential shall have no plans for childbearing, sperm\u002Fegg donation from the time of signing the informed consent form until 72 weeks after the last dose, and shall voluntarily adopt effective contraceptive measures (including their partners). Female subjects must have a negative pregnancy test result during the screening period and before randomization and drug administration, and must not be breastfeeding.\n\nExclusion Criteria:\n\n* At screening, the clinical manifestations are other ulcers or other similar skin lesions caused by non-PG diseases;\n* There is a significant medical history or underlying disease that affects safety.\n* A history of allergy to the study drug or any component of the study drug before screening.\n* A history of alcohol abuse or illegal drug abuse within one year before screening;\n* Having donated approximately 500 mL of blood within 8 weeks before baseline or having plans to donate blood during the study.\n* Other circumstances that the investigator judges may affect the evaluation of the safety and efficacy of the study drug.",{"count":47,"type":20},10,[23],"This study was designed to assess the therapeutic efficacy and safety of SHR-1139 Injection in adult patients with ulcerative pyoderma gangrenosum.",[51],"Pyoderma Gangrenosum","NOT_YET_RECRUITING","2026-01-04",{"date":55,"type":31},"2026-01-13",{"date":57,"type":20},"2026-02-01",{"date":59,"type":20},"2028-06",{"name":37,"class":38},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100529229","phase-4-yangxinshi-tablet-intervention-for-exercise-capacity-in-patients-with-chronic-coronary-syndrome-100529229","NCT06171061","Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome","Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome: Prospective, Multicentre, Randomized, Open-label, Blinded-endpoint Clinical Trial","Inclusion Criteria:\n\n1. age 18-75 years;\n2. CCS patients in stable condition and clearly diagnosed by coronary artery imaging (at least one vessel stenosis ≥ 50%): stable angina, ischaemic cardiomyopathy, asymptomatic or stable symptoms, occult coronary heart disease, acute coronary syndrome (ACS), or \\>3 months after coronary revascularization;\n3. moderately to severely limited exercise tolerance: the maximum 6MWD is \\\u003C 450 m, or the metabolic equivalent (MET) as measured by treadmill cardiopulmonary exercise testing is \\\u003C 5 METs;\n4. voluntary participation and signing of informed consent.\n\nExclusion Criteria:\n\n1. absolute or relative contraindications for the treadmill cardiopulmonary exercise test or 6-minute walk test (6MWT);\n2. serious primary diseases, mental diseases, or malignant tumours that affect lifespan;\n3. pregnancy, intended or suspected pregnancy, miscarriage, breastfeeding, or delivery in the last 6 months;\n4. subjects not suitable for this study in the opinion of the researchers, such as subjects who are participating in other drug clinical trials or intervention studies.","75 Years",{"count":70,"type":20},1200,[72],"PHASE4","This study is a prospective, multicentre, randomized, open-label, blinded-endpoint clinical trial to evaluate the efficacy and safety of Yangxinshi tablets in the treatment of patients with chronic coronary syndrome (CCS).",[75],"Chronic Coronary Syndrome",[77,75],"Yangxinshi","2024-04-16",{"date":80,"type":31},"2024-04-17",{"date":82,"type":31},"2023-12-18",{"date":84,"type":20},"2026-12-31",{"name":37,"class":38},32,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":39},"100493013","prospective-coronary-heart-disease-cohort-100493013","NCT05699629","Prospective Coronary Heart Disease Cohort","A Prospective Longitudinal Multi-Omics Cohort of Patients With Coronary Heart Disease Undergoing Coronary Angiography","Inclusion Criteria:\n\n* Diagnosed as coronary heart disease or with unexplained chest pain needed to undergo coronary angiography.\n* Healthy subjects undergoing routine physical examination in the physical examination department and willing to sign informed consent will be recruited as control subjects.\n\nExclusion Criteria:\n\n* With malignant tumors, infectious diseases and advanced liver diseases.\n* Won't sign an inform consent.",true,{"count":96,"type":20},50000,"OBSERVATIONAL","To evaluate the biomarkers for the prognosis of coronary heart disease, patients with coronary heart disease will be recruited and followed up for at least 2 years.",[100,101],"Coronary Heart Disease","Myocardial Infarction","2023-02-09",{"date":104,"type":31},"2023-02-13",{"date":106,"type":31},"2022-01-21",{"date":108,"type":20},"2027-01-21",{"name":37,"class":38},""]